echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > The first oral medication for secondary progressive multiple sclerosis (SPMS)! Mayzent, a new generation of S1P receptor modulator of Novartis, has been approved by the European Union!

    The first oral medication for secondary progressive multiple sclerosis (SPMS)! Mayzent, a new generation of S1P receptor modulator of Novartis, has been approved by the European Union!

    • Last Update: 2020-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    January 22, 2020 / BIOON / -- Novartis, a Swiss pharmaceutical giant Novartis recently announced that the European Commission (EC) has approved mayzent (siponimod) for the treatment of adult patients with progressive multiple sclerosis (SPMS) secondary to active diseases, as evidenced by imaging features of recurrent or inflammatory activity (for example, Gd enhanced T1 lesions or active, new or expanded T2 lesions) Although the progression of multiple sclerosis (MS) in each patient is unique and influenced by many factors, including the use of DMT, it is estimated that up to 80% of patients with RRMS will eventually transition to SPMS So far, no oral drug has been proved to be effective in delaying the progress of patients' disease This approval makes mayzent the first and only oral drug approved for active SPMS patients in Europe The drug will address a significant unmet medical need in a population of patients with active disease SPMS In the United States, mayzent was approved by FDA in March 2019 for the treatment of adult patients with recurrent multiple sclerosis (RMS), including active secondary progressive multiple sclerosis (SPMS), recurrent remitting multiple sclerosis (RRMS), and clinical isolated syndrome (CIS) In terms of medication, patients do not need first dose observation (FDO, cardiac monitoring at the beginning of treatment), unless there are some pre-existing heart diseases (Note: CIS is defined as the first attack of neurological symptoms, lasting at least 24 hours, caused by inflammation or demyelination of the central nervous system.) it is worth mentioning that in the United States, mayzent is the first treatment drug specifically approved for active SPMS patients in the past 15 years SPMS is a type of MS, which is characterized by progressive and irreversible neurological dysfunction Over time, up to 80% of RRMS patients will transition to SPMS Therefore, early initiation of treatment to slow disability progression is essential for patients Disability progression most often includes, but is not limited to, the impact on mobility, which may lead to the need for walking aids or wheelchairs, bladder dysfunction, and cognitive decline Mayzent can solve the critical unmet medical needs of patients with RRMS in transition period and those with active SPMS in transition Mayzent's approval is based on pioneering data from the phase III expand study This is the largest randomized clinical study conducted in a wide population of SPMS patients with EDSS scores of 3.0 to 6.5 This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of mayozent and placebo in the treatment of SPMS patients The patients in the study represented a typical SPMS population with an average age of 48 years At the beginning of the study, these patients had MS for about 16 years More than 50% of the patients had a median extended disability scale (EDSS) score of 6.0 and relied on Walker The study also investigated a group of patients with active disease (n = 779), defined as patients with Gd enhanced T1 lesions at baseline and / or recurrence in the first two years of the study In addition to signs of activity, baseline characteristics are similar to those of the general population Results from the study population showed that mayzent significantly reduced the risk of confirmed disability progression (CDP) by 3 months (primary endpoint: 21% lower than placebo, P = 0.013), and significantly delayed the risk of CDP by 6 months (26% lower than placebo, P = 0.0058) Data in the active disease subgroup showed that: compared with the placebo group, mayzent significantly delayed the occurrence of 3-month and 6-month CDP by 31% and 37%, respectively, and reduced the annual recurrence rate (arr, confirmed recurrence) by 46% In addition, mayzent has significant favorable results in other related MS disease activity measures, including MRI disease activity and brain volume loss (brain atrophy) In 2019, an additional analysis of the expand study was conducted at the 35th session of the European Committee for the treatment and research of multiple sclerosis (ECTRIMS), indicating that mayzent: can help patients maintain an additional average of more than four years of mobility Reduction of gray matter volume loss at 1 and 2 years is a key driver of disability progression and cognitive decline in SPMS patients Max bricchi, global head of Novartis' neuroscience franchise, said: "as the only drug approved for active SPMS patients, mayzent's approval in Europe is an important milestone, which will help change the dialogue of progressive MS and provide patients and their caregivers with the possibility of expansion For patients with multiple sclerosis, it is extremely important to delay disability progression and maintain cognitive ability so that they can live longer on their own Mayzent demonstrates the mission of Novartis to redesign drugs for underserved people, such as those living in active SPM " Siponimod molecular structure formula (picture source: Wikipedia) the active drug ingredient of mayzent is siponimod, which is a new generation, selective sphingosine 1-phosphate (S1P) receptor regulator, which can selectively bind to S1P1 and S1P5 receptors When combined with S1P1 subtype receptor on lymphocytes, siponimod can prevent lymphocytes from leaving lymph nodes, thus preventing them from entering the central nervous system (CNS) of MS patients, which plays an anti-inflammatory role In addition, siponimod can also enter the CNS and directly bind to the S1P5 and S1P1 subtype receptors on specific cells (oligodendrocytes and astrocytes), which can promote the regeneration of myelin sheath and prevent inflammation In addition to the United States and the European Union, mayzent was approved by the Australian treatment products authority (TGA) in November 2019 to treat adult SPMS patients Novartis is committed to bringing mayzent to patients all over the world Currently, regulatory filings are underway in Switzerland, Japan, Canada and China Mayzent's success is crucial for Novartis, which is facing increasing competition for another $3 billion-a-year blockbuster MS oral drug, gilenya The industry is very optimistic about mayzent's business prospects Some analysts predict that the peak sales of mayzent will be as high as $3 billion after it goes public Source of original text: Novartis announcements EU approval of mayzent ® (siponimod) for result patients with secondary progressive multiple sciences (SPMS) with active disease
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.